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cetani@endoc.med.unipi.itAbstractInactivating mutations of the CDC73 tumor suppressor gene have been reported in
parathyroid carcinomas (PC), in association with the loss of nuclear expression of the
encoded protein, parafibromin. The aim of this study was to further investigate the role
of the CDC73 gene in PC and evaluate whether gene carrier status and/or the loss of
parafibromin staining might have an effect on the outcome of the disease. We performed
genetic and immunohistochemical studies in parathyroid tumor samples from 35 patients
with sporadic PC. Nonsense or frameshift CDC73 mutations were detected in 13 samples
suitable for DNA sequencing. Six of these mutations were germline. Loss of parafibromin
expression was found in 17 samples. The presence of the CDC73 mutation as well as the loss
of parafibromin predicted a high likelihood of subsequent recurrence and/or metastasis
(92.3%, PZ0.049 and 94.1%, PZ0.0017 respectively), but only the latter was associated with
a decreased overall 5- and 10-year survival rates (59%, PZ0.107, and 23%, PZ0.0026
respectively). The presence of both the CDC73 mutation and loss of parafibromin staining
compared with their absence predicted a lower overall survival at 10- (18 vs 84%, PZ0.016)
but not at 5-year follow-up. In conclusion, loss of parafibromin staining, better than CDC73
mutation, predicts the clinical outcome and mortality rate. The added value of CDC73
mutational analysis is the possibility of identifying germline mutations, which will prompt
the screening of other family members.Key Words
" primary hyperparathyroidism
" parathyroid tumorigenesis
" immunostaining
" survivalicen
.0 UEndocrine Connections
(2013) 2, 186–195IntroductionPrimary hyperparathyroidism (PHPT) is one of the most
common endocrine diseases (1). It is usually a sporadic
disorder, but in a minority of cases (!10%) it is a part ofhereditary syndromes, namely multiple endocrine neoplasia
type 1 and 2A, hyperparathyroidism–jaw tumor syndrome
(HPT–JT), and familial isolated hyperparathyroidism (2).sed under a Creative Commons
nported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research F Cetani et al. Parafibromin and CDC73
in parathyroid cancer
2–10 2 :187Sporadic PHPT is due to a single parathyroid adenoma in
80–85% of cases, multiglandular hyperplasia in 10–15%,
and carcinoma in!1%.
The histological diagnosis of parathyroid carcinoma
(PC) is currently restricted to lesions showing unequi-
vocal extra-parathyroidal growth, as evidenced by
perineural invasion, full thickness capsular invasion
with growth into adjacent tissues, extratumoral vascular
invasion, or metastasis (3). A subset of parathyroid
tumors (atypical adenomas) shows pathological features
of PC such as trabecular growth, fibrous bands, marked
cellular atypia, and increased mitotic activity, in the
absence of invasive growth. Thus, the distinction
between benign and malignant parathyroid tumors
cannot be definitively established by histology, unless
there is evidence of invasion of extratumoral vessels,
perineural spaces, or surrounding tissues (thyroid and
other adjacent structures) (4). However, it is noteworthy
that there are patients who develop distant metastases
during the course of the disease who did not show
either extratumoral vascular (40%) or capsular (10–15%)
invasion during histological examination of the original
parathyroid tumor (5, 6).
Advances in the knowledge of the molecular patho-
genesis of PC have been made as a result of the cloning
of CDC73, previously known as HPRT2 the gene res-
ponsible for HPT–JT syndrome, in which there is a high
prevalence of PC (7). Somatic inactivating mutations of
the CDC73 gene have also been reported in up to 70%
of apparently sporadic metastatic PC (8, 9, 10, 11, 12, 13,
14, 15, 16, 17). Notably, in about one-third of patients,
the mutations were germline (8, 12, 14, 15). A lower
prevalence (15%) of CDC73 mutations in PC classified
as malignant only on the basis of histological criteria
(namely the presence of angioinvasion, with or without
capsular invasion and/or distant metastases) has been
reported by Haven et al. (18).
Following the demonstration of CDC73 mutations in
PC, several studies were carried out to evaluate whether
immunostaining of parafibromin, the gene product,
might have some diagnostic utility. Diffuse or focal loss of
parafibromin expression as determined by immunohisto-
chemistry was found in the majority of PC, in one-third
of atypical adenomas, and very rarely in parathyroid
adenomas (8, 9, 10, 11, 12, 13, 19, 20, 21, 22, 23, 24).
The aim of this study was to further investigate the
role of the CDC73 gene in PC and evaluate whether the
gene carrier status and/or the loss of parafibromin staining
might have an effect on the outcome of the disease.http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
Published by Bioscientifica LtdSubjects and methods
Patients
We studied 35 patients with apparently sporadic PC,
collected between 1987 and 2011. Patients underwent
parathyroidectomy (PTx) at the Departments of Surgery of
the University of Pisa (nZ10), Padua (nZ8), Turin (nZ15),
and Genoa (nZ2). Clinical and biochemical data of
interest were obtained from medical records examined
at the end of 2012. The study was approved by our
Internal Review Board and informed consent was obtained
where required.Tissue samples
Thirty-five tumor specimens (26 paraffin-embedded
samples and nine fresh-frozen tissues) were studied. All
samples met the histological diagnosis of PC according to
the recent World Health Organization classification (3).CDC73 gene analysis
Genomic DNA was isolated by standard methods from
fresh or paraffin-embedded parathyroid tissues and
peripheral blood leucocytes or control tissue of patients
in whom the mutation was detected. The entire coding
region and splice site junctions of the CDC73 gene were
PCR amplified and directly sequenced as previously
described (14).Immunohistochemistry
Immunohistochemistry was performed as previously
described (12). In brief, archival sections were deparaffi-
nized in xylene and rehydrated in alcohol. The sections
were incubated for 1 h with the primary MAB (clone
sc-33638 from Santa Cruz Biotecnology), used at the
dilution of 1:50. The antibody is directed against the
portion of the protein corresponding to amino acid
positions 87–100. The sections were then incubated with
biotin-labeled secondary antibody (dilution 1:500) and
subsequently with avidin–biotin complex (Vector
Burlingame, Burlingame, CA, USA) for 30 min each. Sites
of binding were visualized using 3,3-diaminobenzidine as
the chromogen. Finally, sections were counterstained
with hematoxylin, dehydrated, and mounted. Five normal
parathyroid specimens obtained from normocalcemic
patients who had undergone surgery for nodular goiter
were used as controls. In each experiment adjacentThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Clinical and biochemical baseline data for 35 patients
with parathyroid carcinomasa.
Sex (F/M) 17/18
Age at diagnosis (years) 45G15b
Clinical manifestationsc
Nephrolithiasis/nephrocalcinosis (nZ22)c 12 (54%)
Osteoporosis/fragility fractures (nZ22) 17 (77%)
Total serum calcium (mg/dl) (nZ31) 13.5G2.0b
Plasma PTH (pg/ml) (nZ27) 444 (316, 999)d
Follow-up (years) (nZ35) 7 (4, 11)d
aThe figure in parenthesis indicates the number of patients with available
information.
bMeanGS.D.
cSome patients with clinical manifestations had more than one symptom.
dMedian (interquartile range).
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3–10 2 :188stromal/endothelial cells served as an internal positive
control. Parafibromin negative controls consisted of
experiments in which the primary antibody was omitted.
For each tumor sample, six different sections were
analyzed. Cells were scored as positive if specific nuclear
staining was detected, independently of the intensity
of staining. Tumor staining was quantified according to
the percentage of cells showing specific nuclear staining.
Each section was evaluated by two independent observers
(P Viacava and L Torregrossa) who were blinded to the
initial pathological diagnosis and clinical outcome. When
the assessment of the percentage of positive cells differed
between the two observers, the disagreements were
resolved by reaching a consensus after joint review using
a conference microscope.Statistical analysis
Results were expressed as means (GS.D.) (for normally
distributed continuous variables), median and inter-
quartile range (for non-normally distributed continuous
variables), or prevalence, as appropriate. Differences
among patient groups were tested by Mann–Whitney
U test, c2 test, or Fisher test, as appropriate. Differences in
the overall survival (time to death of the disease) among
patient groups were evaluated by the Kaplan–Meier
method, and P values were calculated by the log-rank test.
A P value of !0.05 was considered as statistically
significant.Results
Patients
The clinical and biochemical characteristics of patients are
summarized in Tables 1 and 2. The mean age at diagnosis
was 45 years and there was no gender preference. The
majority of patients had kidney and bone involvement.
Twenty-five (71.4%) patients had recurrence and/or
metastases and 18 of them died of the disease after a
median follow-up of 5.5 years (interquartile range 4, 8).
Ten patients had no evidence of recurrence and/or
metastases and were all alive after a median follow-up of
9.5 years (7, 13).CDC73 genetic analysis
The genetic analysis of the entire coding sequence and
splice sites was performed in 32 out of 35 (91%) tumor
samples. In the remaining three samples, despite usinghttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
Published by Bioscientifica Ltddifferent protocols for DNA extraction, DNA sequencing
was incomplete and therefore these samples were excluded
from subsequent analyses (Table 2). ACDC73mutation was
detected in 13 out of 32 (41%) tumors; a double mutation
was found in two cases (numbers 27 and 43). Sample no. 43
harbored two unreported frameshift mutations, 1-bp
deletions in exons 1 (c.60delG) and 3 (c.248delT), which
predict an alteration of the reading frame with a truncation
at codons 20 (Val20ValfsX6) and 83 (Ile83IlefsX26). All
mutations resulted in a premature stop codon. Five
mutations were localized in exon 1, three in exon 4, three
in exon 2, two in exon 7, and one in exon 5 (Fig. 1).
Sequencing of peripheral blood leucocytes or control
tissue from patients carrying the CDC73 mutation showed
that six mutations (E115X in three cases, R234X in two,
and R139X in one) were germline. Patients carrying the
same mutation were apparently unrelated, even though a
common ancestor could not be excluded. There was no
statistically significant difference in the age at diagnosis
between patients carrying a somatic or a germline
mutation, even though the mean age was higher in the
former group (50G8 vs 38G16, PZ0.094).
The sensitivity, specificity, positive and negative
predictive values of the presence of CDC73 mutation are
reported in Table 3.Immunohistochemistry
Nuclear parafibromin staining was evident in almost all
cells in the normal parathyroid specimens as well as in the
endothelial cells within the parathyroid tumors (Fig. 2).
Immunohistochemistry was performed in 34 out of 35
specimens (Table 2). Immunostaining for parafibromin
was negative (percentage of nuclear staining in !5% of
cells) in 17 out of 34 (50%) tissue samples. The remainingThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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c.25C>T*
c.60delG
c.64G>T
c.70G>T
c.182T>A
c.197dupA
c.195dupT
c.248delT
c.415C>T c.700C>T*
1776543215′ 3′
c.343G>T**
Figure 1
A schematic representation of the CDC73 gene showing the position of the
different identified mutations. Mutations are designated according to the
latest nomenclature recommendations of the Human Genome Variation
Society. Mutations in bold are germline. Mutations found in two or three
patients are indicated by (*) and (**) respectively.
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5–10 2 :19017 tumor samples were scored as positive, with a
percentage of positive cells ranging between 10 and 80%
(median (interquartile range) 30 (10, 30)). A faint
cytoplasmic staining was also observed in the normal
parathyroid gland as well as in some parathyroid tumors.
Representative cases are shown in Fig. 2.
The sensitivity, specificity, positive and negative
predictive values of the loss of parafibromin immuno-
staining are reported in Table 3.Impact of the CDC73 or parafibromin status on
the outcome
The median duration of follow-up was 7 years (inter-
quartile range 4, 11). The survival at 1, 5, 10, and 15 years
was 97, 72, 50, and 36% respectively (Fig. 3).
CDC73mutation " CDC73 mutational data were avail-
able in 32 out of 35 patients. As shown in Fig. 4A, there
was a borderline statistically significant association
between the mutational status and the outcome.
In particular, the presence of the CDC73 mutation
predicted a high likelihood of subsequent recurrenceTable 3 Diagnostic value (%) of the presence
immunostaining in the diagnosis of parathyroid c
CDC
Sensitivity (95% CI)
Specificity (95% CI)
Positive predictive value (95% CI)d
Negative predictive value (95% CI)d 1
aA series of 22 parathyroid adenomas previously cha
immunostaining was used as a control (Cetani et al. (12)).
bCDC73 mutational data were available in 32 patients.
cParafibromin immunostaining data were available for 34 p
dPositive and negative predictive values are calculated given
our Institution of 0.5% among patients with primary hype
http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
Published by Bioscientifica Ltdand/or metastasis (92.3%; PZ0.049). However, the overall
5- and 10-year survivals did not differ between patients
carrying or not carrying the CDC73 mutation (PZ0.971
and PZ0.328 respectively; Fig. 5A).
As mentioned earlier, six out of 13 patients carried
a CDC73 germline mutation. We found that the type of
mutation (somatic or germline) had no effect on the
outcome as all but one patient with germline mutation
had recurrence and/or metastases. Moreover, there was
no statistically significant difference in the survival rate
between patients carrying a somatic (none out of seven)
or a germline (two out of six) mutation (PZ0.192), nor
in the mean time elapsed between diagnosis and death
(7 years in both groups).
Parafibromin status " Parafibromin immunostaining
data were available in 34 out of 35 patients. As shown in
Fig. 4B, there was a statistically significant association
between the immunostaining results and the outcome.
In particular, the loss of parafibromin predicted a high
likelihood of subsequent recurrence and/or metastasis
(94.1%, PZ0.0017). Moreover, there was an inverse
statistically significant association between mortality andof CDC73 mutation and loss of parafibromin
arcinomaa.
73 mutationb Loss of parafibrominc
41 (24–59) 50 (32–68)
95 (77–99) 95 (77–92)
4 (0–10) 5 (0–12)
00 (98–100) 100 (98–100)
racterized for CDC73 mutations and parafibromin
atients.
the estimated prevalence of parathyroid carcinoma at
rparathyroidism.
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Figure 2
Immunohistochemical staining of parafibromin. (A) Normal parathyroid
gland. The parathyroid cells show a diffuse nuclear immunoreactivity
associated with a moderate cytoplasmatic staining (!200). (B) Normal
parathyroid gland, negative control (omission of primary antibody). No
nuclear staining is evident (!200). (C) A representative case of parathyroid
carcinoma scored as negative. The neoplastic cells are completely negative
for parafibromin. The positive staining of non-neoplastic stromal cells
(arrow) provides an internal positive control (!200). (D) A representative
case of parathyroid carcinoma scored as positive. The neoplastic cells show
a diffuse nuclear and cytoplasmatic immunoreactivity for parafibromin.
The adjacent rim of normal parathyroid tissue (arrows) shows a diffuse
immunoreactivity for parafibromin (!200).
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Figure 3
Overall survival in 35 patients with parathyroid carcinoma.
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6–10 2 :191the percentage of positive cells (PZ0.006). The overall
5-year survival did not differ between patients with loss of
parafibromin staining compared with patients with
retained parafibromin expression (59 vs 87%, PZ0.107;
Fig. 5B). Conversely, the 10-year survival was significantly
lower in the former than in the latter group (23 vs 87%,
PZ0.0026).
Combined effect of CDC73 mutation and parafi-
bromin status " CDC73 mutational and parafibromin
immunostaining data were available for 31 patients.
CDC73 mutation associated with the loss of parafibromin
was found in 11 tumor samples and either CDC73
mutation or loss of parafibromin in six. No CDC73
mutation or loss of parafibromin staining was observed
in the remaining 14 tumor samples. As shown in Fig. 6,
there was a statistically significant association between
CDC73 mutation/parafibromin status and the outcome of
PC (PZ0.015). Indeed, ten out of the 11 patients with
mutated tumors and loss of parafibromin died of
the disease. On the other hand, the majority of patients
who had neither CDC73 mutation nor loss of
parafibromin staining were still alive and free of diseasehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
Published by Bioscientifica Ltd(seven out of nine) after a median follow-up of 10 years
(interquartile range 7, 19), or still alive but with the
disease (nZ4) after a median follow-up of 4.5 years
(interquartile range 3, 6.5).
The overall 5-year survival in the 11 patients carrying
the CDC73 mutation and showing loss of parafibrominThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 4
(A) Effect of CDC73 mutational status on local recurrence and/or metastases
in 32 patients with parathyroid carcinoma. MutC, mutation positive;
MutK, mutation negative; Rec/MetC, development of recurrence and/or
metastases; Rec/MetK, no development of recurrence and/or metastases.
(B) Correlation of parafibromin staining results with local recurrence
and/or metastases in 34 patients with parathyroid carcinoma. StainingK,
loss of parafibromin; StainingC, retained parafibromin expression;
Rec/MetC, development of recurrence and/or metastases; Rec/MetK,
no development of recurrence and/or metastases.
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7–10 2 :192staining did not differ from that of the 14 patients with
any of these negative prognostic factors (64 vs 84%,
PZ0.337) (Fig. 5C). Conversely, the 10-year survival was
significantly lower in the former than in the latter group
(18 vs 84%, PZ0.016).
Figure 5
(A) Survival rates according to the presence or absence of CDC73 mutation.
The 10-year survival rates did not differ significantly between the two
groups of patients. (B) Survival rates according to the loss of parafibromin.
Loss of parafibromin staining was associated with a statistically significant
decrease in the 10-year survival. (C) Survival rates according to the presence
or absence of CDC73 mutation and loss of parafibromin. The presence of
both abnormalities was associated with a statistically significant decrease
in the 10-year survival.Discussion
This study was undertaken to shed light on the molecular
mechanisms involved in parathyroid cancer development
and metastatic spread. Current evidence indicates that thehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
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This work is licensed under a Creative Commons
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Figure 6
Combined effect of CDC73 mutational and parafibromin
immunostaining results on the outcome in 31 patients with parathyroid
carcinoma.
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8–10 2 :193CDC73, the gene responsible for HPT–JT syndrome, which
is characterized by a high prevalence of PC, might be a
candidate gene. Abnormalities of the CDC73 gene and its
protein, parafibromin, were reported in several series of
PC, but their rate differed according to the diagnostic
criteria used in different studies (4, 5, 6).
Mutations of the CDC73 gene were detected in up to
75% of PC from patients who had local invasion and/or
metastases at initial diagnosis or during the follow-up.
Conversely, a lower rate (15%) was found in a series
which included patients who fulfilled the histological
diagnosis of PC, but had incomplete follow-up data (18).
Based on these findings, it might be hypothesized that
patients whose tumors carry the CDC73 mutation, as
compared with those who do not, might have a worse
prognosis.
Herein, we confirm that CDC73 mutations are rather
common (48%) in patients with PC. The mutations were
scattered along the entire coding region of the gene, but
60% of them were located in exons 1, 2, and 7, the sites
harboring up to 85% of mutations reported so far (25). As
described in other series (8, 12, 14, 15), 40% of mutations
were germline. The percentage of CDC73 mutation-
positive tumors was lower than we previously detected
in patients with PC (82%) who had local invasion and/or
metastases at initial surgery or during the follow-up
(12, 14). In this study, this apparent discrepancy is
probably due to the inclusion of patients (15 out of 35)
whose diagnosis of PC was only based on histological
criteria. Only one of these patients harbored the CDC73
mutation. The presence of the CDC73 mutation in abouthttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
Published by Bioscientifica Ltdhalf of the patients with PC reported in the literature,
together with its rare occurrence in parathyroid adenomas
(7, 8, 14, 16, 26), indicates that it might be involved in PC
development and predicts a malignant behavior. Taken
together, the current evidence indicates that the finding of
a CDC73 mutation may be an useful diagnostic and
prognostic tool, but its absence does not exclude the
diagnosis of PC nor a potential malignant behavior.
Moreover, the observation that about half of the patients
with PC, as well as half of those who had an aggressive
tumor, do not carry a CDC73 mutation raises the question
of whether large CDC73 gene deletions (27) or alterations
of its promoter methylation (28, 29), or other yet
unknown predisposing genes might be involved.
CDC73 mutations may impair the expression of
parafibromin and its focal/global loss at, as determined
by immunohistochemistry, was reported in up to 100% of
cases (8, 9, 10, 11, 12, 13, 22, 24). Differences in the rate of
parafibromin loss among several studies may be due to the
use of different methodologies and scoring systems.
In this study loss of parafibromin was a rather
common finding (64%), but the rate of loss was lower
than we previously reported (100%) in PC patients who
had local invasion and/or metastases at initial surgery or
during follow-up (12). Conversely, loss of parafibromin
was detected only in one of the ten (10%) patients in the
follow-up, whose diagnosis was only based on classic
histological features.
Loss of parafibromin was generally associated with
CDC73 mutations, which resulted in a truncated protein.
Discrepant results were observed in six cases: loss of
parafibromin and no CDC73 mutation in four tumor
samples and the opposite in two. Loss of staining in the
absence of mutations detected by direct sequencing of the
coding and splice-sites regions could be due to mutations
in the promoter, regulatory regions, introns, and 5 0 or
3 0-UTRs, large whole/partial gene deletions or to abnorm-
alities in the post-transcriptional processing of the protein
(27, 28, 30, 31).
As previously discussed for the CDC73 mutation, the
loss of parafibromin in a large proportion of PC indicates
that it might contribute to PC development and also
predict a malignant behavior. Interestingly, all but one of
the eight PC with biologically malignant behavior and
retained parafibromin expression did not carry the CDC73
mutation, suggesting that other genetic abnormalities
might be responsible for PC in these cases.
PC has a typically indolent, but progressive, clinical
course. Most patients with recurrent disease ultimately
succumb to the effects of hypercalcemia, rather than toThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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9–10 2 :194direct tumor invasion or distant metastases (4). The
presence of gross local invasion and/or distant metastases
at initial surgery definitely predict a fatal outcome.
On the other hand, a complete resection of the primary
tumor allows for the greatest likelihood of cure
(32, 33, 34). In this study, we confirm that PC has an
indolent course in a substantial proportion of patients.
As a matter of fact, the 5- and 10-year survival rates
were 72.4 and 49.7% respectively. Similar findings were
reported by Witteveen et al. (10) (60 and 40% at 5- and
10-year follow-up respectively) and Harari et al. (32) (78.3
and 66.7% at 5- and 10-year follow-up respectively).
In this series, the 5-year survival rate was not predicted
by the presence of CDC73 mutation and/or by the loss
of parafibromin in the primary tumor. The rather high
survival rate at this time probably accounts for this
finding. On the other hand, the loss of parafibromin
allowed better prediction of the long-term outcome in
individual patients, as the 10-year survival declined to
23% in patients with the loss of parafibromin expression
and to 18% when this feature was combined with CDC73
gene mutation. The parafibromin loss either alone or
combined with CDC73 gene mutation and downregula-
tion of the calcium-sensing receptor expression has
recently been reported by Witteveen et al. (10) to have a
negative effect on the survival rate in a series of 23
patients with PC. At variance with our data, these authors
found that the 5-year survival was lower in patients
carrying the CDC73 gene mutation compared with those
who did not.
The strengths of our study are that: i) it includes a large
series of patients with PC whose histological diagnosis has
been established according to the latest WHO guidelines;
ii) the median follow-up after PTx was reasonably long;
iii) the CDC73 mutational analysis and parafibromin
studies were performed in a single center, thus avoiding
potential problems originating from the use of different
techniques and immunohistochemical scoring systems.
There are also some limitations: i) the CDC73 mutational
screening was confined to the coding and splice sites
regions; ii) other putative genes and their protein products
could not be investigated because of the limited quantity
of available tissue samples.
In conclusion, our data indicate that once the
diagnosis of PC is suspected or even established at
histology, it would be appropriate to perform parafibro-
min immunostaining as its loss appears to be an useful
tool not only to confirm the diagnosis of PC but also to
predict a malignant clinical behavior. CDC73 mutational
analysis does not appear to add value to parafibrominhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0046
 2013 The authors
Published by Bioscientifica Ltdstaining in terms of outcome evaluation. Nonetheless,
when parafibromin staining is not available, finding the
CDC73 mutation would also predict a negative outcome.
Independently of these considerations, the complete
evaluation of a patient with PC should include CDC73
mutational analysis, because the identification of a germ-
line mutation, which occurs in about one-third of
patients, would prompt extension of the genetic analysis
to other family members.Declaration of interest
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